Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 ...

Raritan: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved RYBREVANT (amivantamab ...

The Food and Drug Administration (FDA) has approved Rybrevant (amivantamab-vmjw) plus chemotherapy for patients with locally ...

Johnson & Johnson (JNJ) announced that the U.S. Food and Drug Administration approved RYBREVANT (amivantamab-vmjw) in combination ...

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

According to GLOBOCAN 2022 data, lung cancer remains the fourth most common cause of cancer-related mortality in India.

The investigational mRNA cancer ... diagnosed lung cancers and is still associated with a high mortality rate. SCLC tumours often develop resistance to chemotherapy and thus ... A Combination ...

Treatment of non-small cell lung cancer (NSCLC) depends on the stage you're in and can include chemotherapy, surgery, ...

Johnson & Johnson said the Food and Drug Administration approved its treatment of locally-advanced or metastatic non-small cell lung cancer for adults. The treatment, called Rybrevant, has been ...

BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint inhibitor and ...

Hetronifly in combination with chemotherapy was shown to improve survival of patients with extensive stage small cell lung ...

Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally ...